Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol. The company's lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery. It is also developing VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in preclinical stage for X-linked adrenoleukodystrophy. The company was founded in 2012 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-704-4660
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees15
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable
Viking Therapeutics (NASDAQ:VKTX) Frequently Asked Questions
What is Viking Therapeutics' stock symbol?
Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."
How were Viking Therapeutics' earnings last quarter?
Viking Therapeutics Inc (NASDAQ:VKTX) announced its earnings results on Wednesday, March, 13th. The biotechnology company reported ($0.07) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.10) by $0.03. View Viking Therapeutics' Earnings History.
When is Viking Therapeutics' next earnings date?
What price target have analysts set for VKTX?
10 brokerages have issued 12-month price objectives for Viking Therapeutics' shares. Their predictions range from $8.86 to $40.00. On average, they anticipate Viking Therapeutics' share price to reach $22.54 in the next year. This suggests a possible upside of 155.6% from the stock's current price. View Analyst Price Targets for Viking Therapeutics.
What is the consensus analysts' recommendation for Viking Therapeutics?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 9 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Viking Therapeutics.
What are Wall Street analysts saying about Viking Therapeutics stock?
Here are some recent quotes from research analysts about Viking Therapeutics stock:
- 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $31 price target. Our peak sales estimates for VK2806 and VK5211 are based on our U.S. projections, and believe overall that peak sales could be conservative because of the size of the addressable markets, the continuing unmet medical need, and no projections for ex-U.S. sales currently. Our price target is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (4/11/2019)
- 2. Maxim Group analysts commented, "Viking reported 3Q18 with a net loss of ($6.6M) and ended the period with $304M in cash. We have increased expenses going forward as the NASH program moves into later-stage development and additional programs like 0214 move into the clinic." (11/8/2018)
Has Viking Therapeutics been receiving favorable news coverage?
News coverage about VKTX stock has trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Viking Therapeutics earned a news impact score of 1.2 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future.
Are investors shorting Viking Therapeutics?
Viking Therapeutics saw a increase in short interest in March. As of March 29th, there was short interest totalling 32,070,239 shares, an increase of 12.1% from the March 15th total of 28,599,170 shares. Based on an average daily trading volume, of 4,874,050 shares, the days-to-cover ratio is presently 6.6 days. Currently, 50.2% of the shares of the company are short sold. View Viking Therapeutics' Current Options Chain.
Who are some of Viking Therapeutics' key competitors?
Some companies that are related to Viking Therapeutics include Ligand Pharmaceuticals (LGND), Akcea Therapeutics (AKCA), Reata Pharmaceuticals (RETA), Insmed (INSM), Portola Pharmaceuticals (PTLA), Mirati Therapeutics (MRTX), Arena Pharmaceuticals (ARNA), PTC Therapeutics (PTCT), The Medicines (MDCO), Uniqure (QURE), AnaptysBio (ANAB), Endocyte (ECYT), Myokardia (MYOK), Nabriva Therapeutics (NBRV) and Supernus Pharmaceuticals (SUPN).
What other stocks do shareholders of Viking Therapeutics own?
Who are Viking Therapeutics' key executives?
Viking Therapeutics' management team includes the folowing people:
- Dr. Brian Lian, Pres, CEO & Director (Age 53)
- Mr. Michael Morneau, VP of Fin. & Admin. (Age 54)
- Ms. Amy Broidrick, Sr. VP of Corp. Devel.
- Dr. Hiroko Masamune, Chief Devel. Officer (Age 62)
- Ms. Marianne Mancini, Sr. VP of Clinical Operations
When did Viking Therapeutics IPO?
(VKTX) raised $20 million in an initial public offering (IPO) on Wednesday, April 29th 2015. The company issued 2,500,000 shares at $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager.
Who are Viking Therapeutics' major shareholders?
Viking Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.23%) and Woodstock Corp (0.08%). Company insiders that own Viking Therapeutics stock include J Matthew Singleton, Lawson Macartney, Ligand Pharmaceuticals Inc and Michael Morneau. View Institutional Ownership Trends for Viking Therapeutics.
Which institutional investors are buying Viking Therapeutics stock?
VKTX stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC and Woodstock Corp. Company insiders that have bought Viking Therapeutics stock in the last two years include J Matthew Singleton and Lawson Macartney. View Insider Buying and Selling for Viking Therapeutics.
How do I buy shares of Viking Therapeutics?
Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Viking Therapeutics' stock price today?
One share of VKTX stock can currently be purchased for approximately $8.82.
How big of a company is Viking Therapeutics?
Viking Therapeutics has a market capitalization of $635.30 million. The biotechnology company earns $-22,060,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Viking Therapeutics employs 15 workers across the globe.
What is Viking Therapeutics' official website?
How can I contact Viking Therapeutics?
Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-704-4660 or via email at [email protected]
MarketBeat Community Rating for Viking Therapeutics (NASDAQ VKTX)
MarketBeat's community ratings are surveys of what our community members think about Viking Therapeutics and other stocks. Vote "Outperform" if you believe VKTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VKTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
